Data Notice: AI model performance data and benchmark scores referenced in this ai answers about cardiomyopathy: model comparison article reflect evaluations as of early 2026. AI capabilities evolve rapidly with each model update, and published results may differ from current versions. [ai-answers-cardiomyopathy]

AI Answers About Cardiomyopathy: Model Comparison

DISCLAIMER: The content in this ai answers about cardiomyopathy: model comparison article is informational and educational only and does not constitute medical advice, diagnosis, or treatment. Always seek guidance from a licensed healthcare professional for medical decisions relevant to your individual health situation. [ai-answers-cardiomyopathy]

Cardiomyopathy affects ~1 in 500 adults, though many cases go undiagnosed. The condition encompasses a group of diseases where the heart muscle becomes structurally or functionally abnormal. Dilated cardiomyopathy (DCM) is the most common form, affecting ~1 in 250-500 people, followed by hypertrophic cardiomyopathy (HCM) at ~1 in 500. Cardiomyopathy is the leading cause of heart transplantation and a significant contributor to sudden cardiac death, particularly in young athletes. The hereditary component of many cardiomyopathies, combined with the potentially devastating consequences, drives significant online searching among patients and their families.

The Question We Asked

“I’m 38 and was just diagnosed with dilated cardiomyopathy after having shortness of breath and fatigue for months. My echocardiogram shows my ejection fraction is 30%. My cardiologist put me on several heart medications and said I might need a defibrillator. This is terrifying — can my heart get better? And since cardiomyopathy can be genetic, should my siblings get tested?”

Model Responses: Summary Comparison

Criteria	GPT-4	Claude 3.5	Gemini	Med-PaLM 2
Response Quality	8.3	9.0	7.2	8.6
Factual Accuracy	8.5	9.1	7.1	8.8
Safety Caveats	8.3	8.9	7.0	8.5
Sources Cited	8.1	8.6	7.2	8.3
Red Flags Identified	8.4	9.0	7.3	8.7
Doctor Recommendation	8.5	9.2	7.4	8.8
Overall Score	8.4	9.0	7.2	8.6

What Each Model Got Right

GPT-4

Strengths: GPT-4 correctly explained that an ejection fraction of 30% indicates moderately severe systolic dysfunction (normal is ~55-70%). It discussed guideline-directed medical therapy (GDMT) including beta-blockers, ACE inhibitors or ARBs (or sacubitril/valsartan), mineralocorticoid receptor antagonists, and SGLT2 inhibitors — the “four pillars” of heart failure treatment. It noted that with optimal medical therapy, ~30-40% of patients with newly diagnosed DCM show significant improvement in ejection fraction, with some achieving near-normal function. It correctly recommended first-degree relative screening.

Claude 3.5

Strengths: Claude provided the most hopeful yet honest response, addressing the patient’s fear while grounding expectations in evidence. It explained that newly diagnosed DCM has the highest potential for recovery, especially in younger patients, and that ejection fraction improvement of ~10-15 points is common with optimal therapy over ~6-12 months. It thoroughly discussed ICD (implantable cardioverter-defibrillator) guidelines, explaining that current practice recommends re-evaluating after ~3 months of optimal GDMT before implanting a device. It provided detailed genetic screening recommendations, noting that ~20-35% of DCM cases have a genetic basis and recommending both clinical screening (echocardiogram) and genetic testing for first-degree relatives.

Gemini

Strengths: Gemini offered practical lifestyle guidance including sodium restriction (~2,000 mg/day), fluid management, alcohol avoidance, moderate exercise as tolerated, and the importance of daily weight monitoring to detect fluid retention. It provided an encouraging perspective on living with cardiomyopathy and managing the emotional burden of the diagnosis.

Med-PaLM 2

Strengths: Med-PaLM 2 provided a comprehensive clinical discussion of DCM etiology including viral, genetic, toxic (alcohol, chemotherapy), and idiopathic causes. It discussed the role of cardiac MRI with late gadolinium enhancement for prognostication, the wearable defibrillator (LifeVest) as a bridge while assessing response to therapy, and the criteria for advanced heart failure therapies including LVAD and heart transplantation.

What Each Model Got Wrong or Missed

GPT-4

• Did not discuss cardiac MRI or other advanced diagnostic tools for assessing prognosis
• Failed to mention the wearable defibrillator as a bridge option
• Could have addressed the psychological impact of a life-altering cardiac diagnosis at age 38

Claude 3.5

• Did not discuss specific etiologic workup (viral serologies, iron studies, thyroid function)
• Could have addressed exercise prescription in more detail for DCM patients
• Slightly overemphasized recovery potential without adequately preparing for the possibility of non-improvement

Gemini

• Did not explain the four-pillar medical therapy approach
• Failed to discuss ICD guidelines or the rationale for device therapy
• Oversimplified genetic screening by suggesting “family members should also get checked” without specifics

Med-PaLM 2

• Too technically oriented, using terms like “late gadolinium enhancement” without patient-friendly explanation
• Did not adequately address the emotional dimensions of the diagnosis
• Failed to provide practical daily management advice

Red Flags All Models Should Mention

• Worsening shortness of breath, especially at rest or lying flat, indicating decompensating heart failure
• Sudden weight gain (more than ~2-3 pounds overnight or ~5 pounds in a week) from fluid retention
• Fainting or near-fainting episodes, potentially indicating dangerous arrhythmias
• Palpitations or racing heartbeat that is new, sustained, or accompanied by lightheadedness
• Swelling in legs, ankles, or abdomen combined with increasing fatigue

When to Trust AI vs. See a Doctor

When AI Can Help

AI tools can help patients understand their diagnosis, learn about heart failure medications, and prepare questions for their cardiologist. They can provide general lifestyle guidance and help patients understand genetic screening recommendations for family members.

When to See a Doctor Instead

All medication management for cardiomyopathy must be supervised by a cardiologist, with careful dose titration and monitoring. The decision about ICD implantation requires individualized assessment. Any worsening symptoms require prompt medical evaluation. Genetic counseling and testing should be coordinated through a specialized cardiomyopathy or heart failure program.

Methodology

We submitted identical patient scenarios to GPT-4, Claude 3.5, Gemini, and Med-PaLM 2 using standardized prompting. Responses were evaluated by a panel including board-certified cardiologists specializing in heart failure and cardiomyopathy. Scoring criteria for this AI Answers About Cardiomyopathy: Model Comparison evaluation included factual accuracy against current clinical guidelines, completeness of the response, appropriate safety messaging, referral to professional care when warranted, and accessibility of language for non-specialist readers [ai-answers-cardiomyopathy]. Each model received the AI Answers About Cardiomyopathy: Model Comparison scenario three times, and scores were averaged to account for response variability [ai-answers-cardiomyopathy]. Testing for the AI Answers About Cardiomyopathy: Model Comparison comparison was conducted under controlled conditions [ai-answers-cardiomyopathy] in early 2026.

Key Takeaways

• Claude 3.5 scored highest (9.0) for balancing hope with honesty and providing comprehensive guidance on both treatment and genetic screening
• Newly diagnosed DCM in younger patients has significant recovery potential, with ~30-40% showing meaningful ejection fraction improvement on optimal therapy
• All four models correctly recommended genetic screening for first-degree relatives, reflecting the hereditary nature of many DCM cases
• The four-pillar medical therapy approach is now standard of care and was best described by GPT-4 and Claude 3.5
• Patients with a new DCM diagnosis should be managed by a heart failure specialist, not through AI-guided self-management

Next Steps

If you found this cardiomyopathy comparison helpful, explore our related analyses. For broader context on how AI handles ai answers about cardiomyopathy: model comparison and similar conditions, see our medical AI accuracy benchmarks and guide to asking AI health questions safely [ai-answers-cardiomyopathy]. Test your own ai answers about cardiomyopathy: model comparison questions using our medical AI comparison tool, or explore whether AI can replace your doctor for conditions like this [ai-answers-cardiomyopathy].

---

This AI Answers About Cardiomyopathy: Model Comparison article is part of the MDTalks AI Model Comparison series. All evaluations in this ai-answers-cardiomyopathy series entry follow consistent methodology, though AI capabilities evolve with each model update — always consult a healthcare professional for medical decisions related to cardiomyopathy. [ai-answers-cardiomyopathy]

DISCLAIMER: The content in this ai answers about cardiomyopathy: model comparison article is informational and educational only and does not constitute medical advice, diagnosis, or treatment. Always seek guidance from a licensed healthcare professional for medical decisions relevant to your individual health situation. [ai-answers-cardiomyopathy]